6533b855fe1ef96bd12afe37
RESEARCH PRODUCT
GLP-1 receptor agonists in NAFLD.
Jean-michel PetitBruno Vergèssubject
medicine.medical_specialtySteatosisEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseType 2 diabetesGastroenterologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyFibrosisWeight lossInternal medicineInternal MedicineHumansHypoglycemic AgentsMedicineReceptorGlucagon-like peptide 1 receptorGLP-1 receptor agonistsbusiness.industryFatty livernutritional and metabolic diseasesGeneral Medicine[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseFibrosisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030211 gastroenterology & hepatologytype 2 diabetesSteatosismedicine.symptombusinessNon-alcoholic fatty liver diseasedescription
IF 4.101; International audience; Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-04-01 |